.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,972,973

« Back to Dashboard

Details for Patent: 5,972,973

Title: Sulfonylurea-glitazone combinations for diabetes
Abstract:Combinations of a sulfonylurea antidiabetic agent and a glitazone antidiabetic agent are useful for treating diabetes mellitus and improving glycemic control.
Inventor(s): Whitcomb; Randall Wayne (Ann Arbor, MI)
Assignee: Warner-Lambert Company (Morris Plains, NJ)
Filing Date:Oct 16, 1998
Application Number:09/173,911
Claims:1. A composition comprising from about 3 mg to about 250 mg of a sulfonylurea antidiabetic agent and about 5 mg to about 50 mg of rosiglitazone (BRL49653), said amounts of sulfonylurea and rosiglitazone being synergistic for the treatment of non-insulin dependent diabetes mellitus in humans.

2. A composition of claim 1 wherein the sulfonylurea is selected from glisoxepid, glyburide, acetohexamide, chlorpropamide, glibornuride, tolbutamide, tolazamide, glipizide, gliclazide, gliquidone, glyhexamide, phenbutamide, and tolcyclamide.

3. A composition of claim 5 comprising rosiglitazone and glyburide.

4. A method of treating non-insulin dependent diabetes mellitus in humans comprising administering to a patient in need of treatment from about 3 mg to about 250 mg of a sulfonylurea antidiabetic agent in combination with about 5 mg to about 50 mg of rosiglitazone, said amounts of sulfonylurea and rosiglitazone being synergistic for the treatment of non-insulin dependent diabetes mellitus in humans.

5. A method according to claim 4 wherein the sulfonylurea antidiabetic agent is selected from glisoxepid, glyburide, acetohexamide, chlorpropamide, glibornuride, tolbutamide, tolazamide, glipizide, gliclazide, gliquidone, glyhexamide, phenbentamide, and tolcyclamide.

6. A method of treating non-insulin dependent diabetes mellitus in humans comprising administering to a patient in need of treatment from about 3 mg to about 250 mg of a sulfonylurea antidiabetic agent in combination with about 5 mg to about 10 mg of rosiglitazone, said amounts of sulfonylurea and rosiglitazone being synergistic for the treatment of non-insulin dependent diabetes mellitus in humans.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc